ProQR Therapeutics NV (PRQR)
3.64
+0.01
(+0.28%)
USD |
NASDAQ |
Nov 05, 14:34
ProQR Therapeutics Total Liabilities (Quarterly): 91.32M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 91.32M |
| March 31, 2024 | 96.17M |
| December 31, 2023 | 106.66M |
| September 30, 2023 | 101.29M |
| June 30, 2023 | 104.86M |
| March 31, 2023 | 108.29M |
| December 31, 2022 | 112.22M |
| September 30, 2022 | 56.21M |
| June 30, 2022 | 96.18M |
| March 31, 2022 | 100.47M |
| December 31, 2021 | 109.09M |
| September 30, 2021 | 78.07M |
| June 30, 2021 | 53.33M |
| March 31, 2021 | 49.74M |
| December 31, 2020 | 51.88M |
| September 30, 2020 | 49.43M |
| June 30, 2020 | 15.67M |
| March 31, 2020 | 24.58M |
| December 31, 2019 | 26.55M |
| September 30, 2019 | 23.68M |
| June 30, 2019 | 22.76M |
| Date | Value |
|---|---|
| March 31, 2019 | 23.37M |
| December 31, 2018 | 20.07M |
| September 30, 2018 | 19.28M |
| June 30, 2018 | 17.12M |
| March 31, 2018 | 15.80M |
| December 31, 2017 | 16.53M |
| September 30, 2017 | 15.14M |
| June 30, 2017 | 13.27M |
| March 31, 2017 | 13.24M |
| December 31, 2016 | 13.12M |
| September 30, 2016 | 12.77M |
| June 30, 2016 | 14.46M |
| March 31, 2016 | 12.69M |
| December 31, 2015 | 11.27M |
| September 30, 2015 | 10.29M |
| June 30, 2015 | 10.54M |
| March 31, 2015 | 8.291M |
| December 31, 2014 | 7.105M |
| September 30, 2014 | 6.885M |
| June 30, 2014 | 6.929M |
| December 31, 2013 | 6.342M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
15.67M
Minimum
Jun 2020
112.22M
Maximum
Dec 2022
75.37M
Average
91.32M
Median
Jun 2024
Total Liabilities (Quarterly) Benchmarks
| uniQure NV | 633.74M |
| Merus NV | 141.42M |
| argenx SE | -- |
| Pharming Group | 199.72M |
| Pharvaris NV | 20.45M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 126.54M |
| Shareholders Equity (Quarterly) | 35.22M |
| Debt to Equity Ratio | 0.1351 |
| Current Ratio | 2.730 |
| Net Debt Paydown Yield | 0.34% |